M-A: Association of Sodium-Glucose Cotransporter 2 Inhibitors with cardiovascular outcomes in patients with Type 2 Diabetes and other risk factors for cardiovascular disease.
20 Jan, 2022 | 08:42h | UTC
Commentary on Twitter
This meta-analysis found that use of SGLT2-Is was associated with lower occurrence of cardiovascular death or hospitalization for heart failure by 33% in high-risk patients. @mukul_bhattarai @AkcharAl @AbhiKulk82 @mominsiddique01 @Mohsin_Salih19 https://t.co/omPP6Qwofg
— JAMA Network Open (@JAMANetworkOpen) January 5, 2022